471 related articles for article (PubMed ID: 20823422)
21. Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients.
Der SD; Sykes J; Pintilie M; Zhu CQ; Strumpf D; Liu N; Jurisica I; Shepherd FA; Tsao MS
J Thorac Oncol; 2014 Jan; 9(1):59-64. PubMed ID: 24305008
[TBL] [Abstract][Full Text] [Related]
22. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
Li B; Cui Y; Diehn M; Li R
JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10.
Pepe C; Hasan B; Winton TL; Seymour L; Graham B; Livingston RB; Johnson DH; Rigas JR; Ding K; Shepherd FA;
J Clin Oncol; 2007 Apr; 25(12):1553-61. PubMed ID: 17442999
[TBL] [Abstract][Full Text] [Related]
24. NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma.
Cescon DW; She D; Sakashita S; Zhu CQ; Pintilie M; Shepherd FA; Tsao MS
Clin Cancer Res; 2015 Jun; 21(11):2499-505. PubMed ID: 25739673
[TBL] [Abstract][Full Text] [Related]
25. Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial.
Bennouna J; Senellart H; Hiret S; Vaissiere N; Douillard JY
Lung Cancer; 2011 Oct; 74(1):30-4. PubMed ID: 21371774
[TBL] [Abstract][Full Text] [Related]
26. A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients.
Tang H; Xiao G; Behrens C; Schiller J; Allen J; Chow CW; Suraokar M; Corvalan A; Mao J; White MA; Wistuba II; Minna JD; Xie Y
Clin Cancer Res; 2013 Mar; 19(6):1577-86. PubMed ID: 23357979
[TBL] [Abstract][Full Text] [Related]
27. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.
Tsao MS; Aviel-Ronen S; Ding K; Lau D; Liu N; Sakurada A; Whitehead M; Zhu CQ; Livingston R; Johnson DH; Rigas J; Seymour L; Winton T; Shepherd FA
J Clin Oncol; 2007 Nov; 25(33):5240-7. PubMed ID: 18024870
[TBL] [Abstract][Full Text] [Related]
28. Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: the JBR.10 trial experience.
Gauthier I; Ding K; Winton T; Shepherd FA; Livingston R; Johnson DH; Rigas JR; Whitehead M; Graham B; Seymour L
Lung Cancer; 2007 Mar; 55(3):357-63. PubMed ID: 17141357
[TBL] [Abstract][Full Text] [Related]
29. Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).
Kreuter M; Vansteenkiste J; Fischer JR; Eberhardt WE; Zabeck H; Kollmeier J; Serke M; Frickhofen N; Reck M; Engel-Riedel W; Neumann S; Thomeer M; Schumann C; De Leyn P; Graeter T; Stamatis G; Griesinger F; Thomas M;
J Thorac Oncol; 2016 Jan; 11(1):85-93. PubMed ID: 26762743
[TBL] [Abstract][Full Text] [Related]
30. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.
Chang WJ; Sun JM; Lee JY; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2014 Apr; 84(1):51-5. PubMed ID: 24521819
[TBL] [Abstract][Full Text] [Related]
31. Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy.
Takahashi T; Sakai K; Kenmotsu H; Yoh K; Daga H; Ohira T; Ueno T; Aoki T; Hayashi H; Yamazaki K; Hosomi Y; Chen-Yoshikawa TF; Okumura N; Takiguchi Y; Sekine A; Haruki T; Yamamoto H; Sato Y; Akamatsu H; Seto T; Saeki S; Sugio K; Nishio M; Inokawa H; Yamamoto N; Nishio K; Tsuboi M
Cancer Sci; 2022 Jan; 113(1):287-296. PubMed ID: 34689382
[TBL] [Abstract][Full Text] [Related]
32. Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group.
Ng R; Hasan B; Mittmann N; Florescu M; Shepherd FA; Ding K; Butts CA; Cormier Y; Darling G; Goss GD; Inculet R; Seymour L; Winton TL; Evans WK; Leighl NB; ; ;
J Clin Oncol; 2007 Jun; 25(16):2256-61. PubMed ID: 17538170
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical validation study of 15-gene biomarker panel predictive of benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of JBR.10.
Grieve S; Ding K; Moore J; Finniss M; Ray A; Lees M; Hossain F; Murugesan A; Agar J; Acar C; Taylor J; Shepherd FA; Reiman T
ESMO Open; 2020 Mar; 5(2):. PubMed ID: 32220948
[TBL] [Abstract][Full Text] [Related]
34. Positive expression of pro-opiomelanocortin (POMC) is a novel independent poor prognostic marker in surgically resected non-small cell lung cancer.
Hao L; Zhao X; Zhang B; Li C; Wang C
Tumour Biol; 2015 Mar; 36(3):1811-7. PubMed ID: 25377161
[TBL] [Abstract][Full Text] [Related]
35. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.
Filipits M; Pirker R; Dunant A; Lantuejoul S; Schmid K; Huynh A; Haddad V; André F; Stahel R; Pignon JP; Soria JC; Popper HH; Le Chevalier T; Brambilla E
J Clin Oncol; 2007 Jul; 25(19):2735-40. PubMed ID: 17602078
[TBL] [Abstract][Full Text] [Related]
36. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial.
Douillard JY; Rosell R; De Lena M; Riggi M; Hurteloup P; Mahe MA;
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):695-701. PubMed ID: 18439766
[TBL] [Abstract][Full Text] [Related]
37. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer.
Rosell R; Skrzypski M; Jassem E; Taron M; Bartolucci R; Sanchez JJ; Mendez P; Chaib I; Perez-Roca L; Szymanowska A; Rzyman W; Puma F; Kobierska-Gulida G; Farabi R; Jassem J
PLoS One; 2007 Nov; 2(11):e1129. PubMed ID: 17987116
[TBL] [Abstract][Full Text] [Related]
38. Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer.
Chen DT; Hsu YL; Fulp WJ; Coppola D; Haura EB; Yeatman TJ; Cress WD
J Natl Cancer Inst; 2011 Dec; 103(24):1859-70. PubMed ID: 22157961
[TBL] [Abstract][Full Text] [Related]
39. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
Yue D; Xu S; Wang Q; Li X; Shen Y; Zhao H; Chen C; Mao W; Liu W; Liu J; Zhang L; Ma H; Li Q; Yang Y; Liu Y; Chen H; Wang C
Lancet Respir Med; 2018 Nov; 6(11):863-873. PubMed ID: 30150014
[TBL] [Abstract][Full Text] [Related]
40. A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer.
Guo NL; Dowlati A; Raese RA; Dong C; Chen G; Beer DG; Shaffer J; Singh S; Bokhary U; Liu L; Howington J; Hensing T; Qian Y
EBioMedicine; 2018 Jun; 32():102-110. PubMed ID: 29861409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
